Protease Inhibitors
"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Descriptor ID |
D011480
|
MeSH Number(s) |
D27.505.519.389.745
|
Concept/Terms |
Protease Inhibitors- Protease Inhibitors
- Inhibitors, Protease
- Endopeptidase Inhibitors
- Inhibitors, Endopeptidase
- Protease Inhibitor
- Inhibitor, Protease
- Peptide Hydrolase Inhibitors
- Hydrolase Inhibitors, Peptide
- Inhibitors, Peptide Hydrolase
- Peptide Peptidohydrolase Inhibitors
- Inhibitors, Peptide Peptidohydrolase
- Peptidohydrolase Inhibitors, Peptide
- Protease Antagonists
- Antagonists, Protease
- Antiproteases
- Peptidase Inhibitors
- Inhibitors, Peptidase
|
Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".
This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1981 | 1 | 0 | 1 | 1986 | 1 | 0 | 1 | 1987 | 0 | 1 | 1 | 1988 | 0 | 1 | 1 | 1989 | 1 | 1 | 2 | 1990 | 1 | 0 | 1 | 1991 | 1 | 2 | 3 | 1992 | 0 | 1 | 1 | 1995 | 0 | 1 | 1 | 1996 | 0 | 3 | 3 | 1997 | 0 | 4 | 4 | 1998 | 0 | 3 | 3 | 2000 | 1 | 1 | 2 | 2001 | 0 | 1 | 1 | 2002 | 0 | 3 | 3 | 2004 | 3 | 1 | 4 | 2005 | 0 | 2 | 2 | 2007 | 4 | 0 | 4 | 2008 | 1 | 2 | 3 | 2009 | 3 | 0 | 3 | 2010 | 1 | 1 | 2 | 2011 | 0 | 1 | 1 | 2012 | 1 | 1 | 2 | 2013 | 1 | 0 | 1 | 2014 | 2 | 2 | 4 | 2019 | 1 | 0 | 1 | 2020 | 1 | 0 | 1 | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.
-
Gupta Y, Kumar S, Zak SE, Jones KA, Upadhyay C, Sharma N, Azizi SA, Kathayat RS. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorg Med Chem. 2021 10 01; 47:116393.
-
Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker L. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.
-
Kandimalla R, John A, Abburi C, Vallamkondu J, Reddy PH. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Mol Neurobiol. 2020 Oct; 57(10):4106-4116.
-
Karagodin I, Kalantari S, Yu DB, Kim G, Sayer G, Addetia K, Tayazime S, Weinert L, Yamat M, Uriel N, Lang R, Mor-Avi V. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients. Int J Cardiovasc Imaging. 2020 Feb; 36(2):271-278.
-
Dickinson BC, Packer MS, Badran AH, Liu DR. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014 Oct 30; 5:5352.
-
Zhang J, Liu H, Zhu K, Gong S, Dramsi S, Wang YT, Li J, Chen F, Zhang R, Zhou L, Lan L, Jiang H, Schneewind O, Luo C, Yang CG. Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. Proc Natl Acad Sci U S A. 2014 Sep 16; 111(37):13517-22.
-
Aronsohn A, Jensen D. Interferon-combination strategies for the treatment of chronic hepatitis C. Semin Liver Dis. 2014 Feb; 34(1):30-6.
-
Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, Fitzgerald R, Gong MN, Graham DD, Gunnerson K, Heung M, Jortani S, Kleerup E, Koyner JL, Krell K, Letourneau J, Lissauer M, Miner J, Nguyen HB, Ortega LM, Self WH, Sellman R, Shi J, Straseski J, Szalados JE, Wilber ST, Walker MG, Wilson J, Wunderink R, Zimmerman J, Kellum JA. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med. 2014 Apr 15; 189(8):932-9.
-
Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A. 2014 Mar 18; 111(11):4251-6.
-
Charlton M, Dick T. Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol. 2014 Jan; 60(1):6-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|